HighTide Therapeutics (02511) has disclosed its Monthly Return for the period ended 31 January 2026, confirming no changes in authorized share capital, which remains 1,000,000,000 ordinary shares at a par value of US$0.0001 for a total of US$100,000. The number of issued shares also remained constant at 571,325,668, with no treasury shares recorded.

The filing confirms compliance with the applicable public float requirement at the prescribed 25% threshold. No new share options, warrants, or convertible instruments were issued during the reporting period, and no other movements in issued shares were noted.